Section Arrow
KTRA.NASDAQ
- Kintara Therapeutics
(Financial Status)
Quotes are at least 15-min delayed:2024/05/05 12:20 EDT
Last
 0.1513
-0.0059 (-3.75%)
Day High 
0.1624 
Prev. Close
0.1572 
1-M High
0.24 
Volume 
3.04M 
Bid
0.1503
Ask
0.1514
Day Low
0.1499 
Open
0.1565 
1-M Low
0.101 
Market Cap 
6.14M 
Currency USD 
P/E -- 
%Yield
10-SMA 0.14 
20-SMA 0.13 
50-SMA 0.11 
52-W High 5.6 
52-W Low 0.081 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-5.22/-0.70
Enterprise Value
6.14M
Balance Sheet
Book Value Per Share
-0.27
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
JAGXJaguar Health0.318+0.0248+8.46%-- 
VAXXVaxxinity0.1411+0.0369+35.41%-- 
DNAGinkgo Bioworks Holdings0.955+0.0939+10.90%-- 
ARDXArdelyx8.72+1.93+28.42%-- 
IBRXImmunityBio9.15+0.18+2.01%-- 
Quotes are at least 15-min delayed:2024/05/05 12:20 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.